检索结果-南通市图书馆

在线全文

学校读者我要写书评

暂无评论

集合功能不足致阅读困难1例

眼视光学杂志 2009年第2期11卷 101-101,106页

作者：王科余琼武第三军医大学西南眼科医院重庆400038

患者，女，27岁，近距离工作多，未戴镜，主诉因从小视近出现头痛、眼胀、视力模糊，加重1年就诊．曾被诊断为神经性头痛，服药治疗半年无效。检查：裸眼远视力：OD，0．5，OS，0．7；近距视力：OU，1．0。遮盖试验远距为正位，近距为... 详细信息

患者，女，27岁，近距离工作多，未戴镜，主诉因从小视近出现头痛、眼胀、视力模糊，加重1年就诊．曾被诊断为神经性头痛，服药治疗半年无效。检查：裸眼远视力：OD，0．5，OS，0．7；近距视力：OU，1．0。遮盖试验远距为正位，近距为外隐斜。主觉验光：OD,-0．25DS／-0．25DC×80°（1．2）；OS，-0．25DC×95°（1．2），眼前节及眼底情况（-）。根据表1所述的眼动参数测量结果，近距外隐斜度数增加，集合近点后退，结合主诉下午视近眼胀、模糊症状加重，诊断为集合功能不足。给予对症治疗，方法为集合训练仪及同视机融合性辐辏训练，每天2次，每次10～15min，2周后症状稍改善。因患者本人不能坚持训练，改为配戴框架眼镜治疗，在家进行推进训练，每天2次，

关键词：集合不足视近疲劳

不同阅读距离的调节准确度与早发性近视眼的相关性

在线全文

学校读者我要写书评

暂无评论

中华眼科杂志 2016年第7期52卷 520-524页

作者：余琼武张萍周善璧胡雁吉明霞骆益春游海玲姚枝秀重庆医科大学附属大学城医院眼科 401331

目的探讨早发性近视眼儿童的调节准确度与早发性近视眼发生发展的相关性。方法病例对照研究。7—13岁早发性近视眼未矫正者41例，戴镜者39例，正视者37例。运用综合验光仪双眼融像性交叉柱镜（FCC）测量所有入选者的屈光度数及20、30、4... 详细信息

目的探讨早发性近视眼儿童的调节准确度与早发性近视眼发生发展的相关性。方法病例对照研究。7—13岁早发性近视眼未矫正者41例，戴镜者39例，正视者37例。运用综合验光仪双眼融像性交叉柱镜（FCC）测量所有入选者的屈光度数及20、30、40、50cm阅读距离下的调节准确度。比较3个组之间以及不同阅读距离之间调节准确度的差异，分析调节准确度与近视眼屈光度数的相关性。3个组之间性别比例、调节滞后比例、调节准确度的差异采用非参数检验，年龄、屈光度数、调节滞后量FCC值的差异采用单因素方差分析，阅读距离与调节准确度之间的相关性、近视眼屈光度与FCC值之间的相关性以及与调节准确度之间的相关性采用Spearman相关分析。结果大部分受试者包括正视眼的调节准确度都存在滞后现象，不同阅读距离的滞后比例分别是75．21％（50cm）、87．18％（40cm）、92．31％（30cm）、98．29％（20cm）。所有受试者随阅读距离的缩短，调节滞后的比例及FCC值增加、调节准确度降低。3个组之间30和20cm调节准确度的差异有统计学意义（30cm：χ2=7．852，P=0．020，20cm：χ2=6．480，P=0．039），其余距离差异无统计学意义（P〉0．05）。3个组之间30和20cmFCC值的差异有统计学意义（30cm：F=3．626，P=0．030；20cm：F=3．703，P=0．028），两两比较，仅近视眼未矫正组FCC值[30cm：（1．25±0．44）D，20cm：（1．76±0．43）D）]与正视组[30cm：（0．95±0．52）D，20cm：（1．41±0．58）D]的差异有统计学意义（30cm：P=0．012，20cm：P=0．008），其余差异无统计学意义（P〉0．05）。近视眼屈光度数与不同阅读距离的调节准确度之间均无显著的相关性，但与20cm的FCC值有显著的相关性（r=0．246，P=0．028）。结论早发性近视眼尤其是未矫正眼随阅读距离的拉近，调节准确度降低的程度较正视眼显著。戴镜可能通过改善调节阈值和敏感度提高了较近阅读距离的调节准确度。早发性近视眼的发生发展与调节准确度可能无关，但是与较近阅读距离（〈30cm）的调节滞后量密切相关，调节滞后量越高，近视屈光度数越高。

关键词：近视调节, 眼阅读眼镜

在线全文

学校读者我要写书评

暂无评论

重庆市某高校教职工疾病与健康危险因素分析

重庆医学 2014年第25期43卷 3325-3328页

作者：杨小红周善璧谢友红余琼武刘灏卢宗亮秦玉何庆莉糜漫天第三军医大学军事预防医学院营养与食品安全研究中心/重庆市营养与食品安全重点实验室重庆400038 重庆医科大学附属大学城医院党政办 401331 重庆医科大学附属大学城医院眼科 401331 重庆医科大学附属大学城医院神经消化中心 401331 重庆医科大学附属大学城医院体检中心 401331

目的了解某高校教师身体状况,为该人群的健康保健提供依据。方法回顾分析该校参检人员的健康信息共1 303例,SPSS17.0统计软件进行数据分析。结果主要检出疾病为结膜炎、脂肪肝、白内障、屈光不正、眼底动脉硬化、高血压;检出健康危险因... 详细信息

目的了解某高校教师身体状况,为该人群的健康保健提供依据。方法回顾分析该校参检人员的健康信息共1 303例,SPSS17.0统计软件进行数据分析。结果主要检出疾病为结膜炎、脂肪肝、白内障、屈光不正、眼底动脉硬化、高血压;检出健康危险因素中前5种依次为血脂异常、超体质量、血压偏高、尿酸偏高、空腹血糖异常。男性结膜炎、脂肪肝、眼底动脉硬化、超体质量、血压偏高、尿酸偏高、空腹血糖异常的检出率明显高于女性(P0.05)。除尿酸偏高(P=0.740)外,不同年龄段所患疾病、存在危险因素显著不同(P<0.01)。糖尿病、高血压的患病率低于全国平均水平。结论该校教师眼睛健康状况不乐观;健康危险因素较多,应针对该人群开展超体质量、血脂异常、血糖异常、血压升高的健康知识教育。

关键词：高校教师疾病健康危险因素预防保健

AL—scan与A超测量眼球生物参数及人工晶状体度数的对比研究

在线全文

学校读者我要写书评

暂无评论

中国实用眼科杂志 2017年第3期35卷 243-246页

作者：陆新婷张萍余琼武张弟波蒙寒花重庆医科大学附属大学城医院眼科重庆401331

目的对比AL-scan和A超测量眼球生物参数及人工晶状体度数的差异，评价AL-scan的临床应用价值。方法临床病例检测方法对照研究。对2015年12月至2016年5月在重庆医科大学附属大学城医院眼科应用AL-scan和A超对拟行白内障手术的患者75例... 详细信息

目的对比AL-scan和A超测量眼球生物参数及人工晶状体度数的差异，评价AL-scan的临床应用价值。方法临床病例检测方法对照研究。对2015年12月至2016年5月在重庆医科大学附属大学城医院眼科应用AL-scan和A超对拟行白内障手术的患者75例（110只眼）进行眼轴长度（AL）、前房深度（ACD）及角膜平均曲率（K）的测量，根据AL分为三组，A组：22 mm≤AL〈24.5 mm 46例（66只眼），B组：24.5 mm≤AL〈26 mm 14例（21只眼），C组：AL≥26 mm 15例（23只眼），应用SRK-T公式计算人工晶状体（IOL）度数，术后随访3月，计算平均绝对误差（MAE）。结果 A超与AL-scan测量AL、ACD在A组及C组中差异有统计学意义（P〈0.05），在B组无统计学意义（P〉0.05）；测量K值在三组中无统计学意义（P〉0.05）。AL-scan在三组中测算MAE分别为（0.32±0.22）、（0.48±0.55）、（0.56±0.46）D，A超分别为（0.34±0.23）、（0.15±0.09）、（0.50±0.38）D，二者之间差异无统计学意义（P〈0.05），测量值之间均具有良好相关性。结论在三组中AL-scan测量所得AL、ACD值均比A超测量值大，在测量IOL度数方面与A超无差别，可应用于术前IOL的测算。

关键词： AL—scan A超眼球生物参数人工晶状体度数白内障

Impairment of liver regeneration by the histone deacetylase inhibitor valproic acid in mice

在线全文

学校读者我要写书评

暂无评论

Journal of Zhejiang University-Science B(Biomedicine & Biotechnology) 2012年第9期13卷 695-706页

作者： Qi KE Rui-na YANG Feng YE yu-jia WANG qiongwu Li LI Hong BU Department of Pathology West China HospitalSichuan UniversityChengdu 610041China Department of Oncology the First Affiliated HospitalHenan University of Science and TechnologyLuoyang 471003China Key Laboratory of Transplant Engineering and Immunology of Ministry of Health West China HospitalSichuan UniversityChengdu 610041China

Background and objective:Liver regeneration is a complex process regulated by a group of genetic and epigenetic factors.A variety of genetic factors have been reported,whereas few investigations have focused on epigenetic regulation during liver *** the present study,valproic acid(VPA),a histone deacetylase(HDAC) inhibitor,was used to investigate the effect of HDAC on liver ***:VPA was administered via intraperitoneal injection to 2/3 partially hepatectomized mice to detect hepatocyte proliferation during liver *** mice were sacrificed,and their liver tissues were harvested at sequential time points from 0 to 168 h after *** synthesis was detected via a BrdU assay,and cell proliferation was tested using *** expressions of cyclin D1,cyclin E,cyclin dependent kinase 2(CDK2),and CDK4 were detected by Western blot *** immunoprecipitation(ChIP) assay was used to examine the recruitment of HDACs to the target promoter regions and the expression of the target gene was detected by Western ***:Immunohistochemical analysis showed that cells positive for BrdU and Ki-67 decreased,and the peak of BrdU was delayed in the VPA-administered ***,cyclin D1 expression was also *** identified B-myc as a target gene of HDACs by complementary DNA(cDNA) *** expression of B-myc increased in the VPA-administered mice after hepatectomy(PH).The ChIP assay confirmed the presence of HDACs at the B-myc ***:HDAC activities are essential for liver *** HDAC activities delays liver regeneration and induces liver cell cycle arrest,thereby causing an anti-proliferative effect on liver regeneration.

关键词： Liver regeneration Epigenetic factors Cell cycle VPA B-myc

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated,EGFR-mutated,advanced non-small cell lung cancer:data froma randomized phase III trial(AENEAS)

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2024年第9期44卷 1005-1017页

作者： Shun Lu Xiaorong Dong Hong Jian Jianhua Chen Gongyan Chen yuping Sun Yinghua Ji ZipingWang Jianhua Shi Junguo Lu Shaoshui Chen Dongqing Lv Guojun Zhang Chunling Liu Juan Li Xinmin yu Zhong Lin Zhuang yu ZhehaiWang Jiuwei Cui Xingxiang Xu Jian Fang Jifeng Feng Zhi Xu RuiMa Jie Hu Nong Yang Xiangdong Zhou XiaohongWu Chengping Hu Zhihong Zhang You Lu Yanping Hu Liyan Jiang Qiming wang Renhua Guo Jianying Zhou Baolan Li Chunhong Hu Wancheng Tong Helong Zhang LinMa yuan Chen Zhijun Jie yu Yao Longzhen Zhang JieWeng Weidong Li Jianping Xiong Xianwei Ye Jianchun Duan Haihua Yang Meili Sun HongyingWei JiaweiWei Zheyu Zhang qiongwu Department of Medical Oncology Shanghai Chest Hospital Shanghai JiaoTong UniversityShanghaiP.R.China Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and TechnologyWuhanHubeiP.R.China Department of Medical Oncology-Chest Hunan Cancer Hospital&The Affiliated Cancer Hospital of Central South University Xiangya School of MedicineChangshaHunanP.R.China Thoracic OncologyMedicine HarbinMedical University Cancer HospitalHarbinHeilongjiangP.R.China Department of Oncology Jinan Central HospitalJinanShandongP.R.China Department of Oncology First Affiliated Hospital of Xinxiang Medical UniversityXinxiangHenanP.R.China Department of Chest Medicine Beijing Cancer HospitalBeijingP.R.China Department of Internal Medicine Linyi Cancer HospitalLinyiShandongP.R.China Department of Respiratory Medicine Nantong Tumor HospitalNantongJiangsuP.R.China Department of Oncology Binzhou Medical University HospitalBinzhouShandongP.R.China Breath Internal Medicine Taizhou Hospital of Zhejiang ProvinceLinhaiZhejiangP.R.China Department of Respiration The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China Department of Lung Internal Medicine Affiliated Tumor Hospital of Xinjiang Medical UniversityUrumqiXinjiangP.R.China Department of Thoracic Oncology Sichuan Cancer HospitalChengduSichuanP.R.China Thoracic Medical Oncology Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)HangzhouZhejiangP.R.China Department of Thoracic Oncology The Fifth Subsidiary Sun Yat-sen University HospitalZhuhaiGuangdongP.R.China Department of Oncology The Affiliated Hospital of QingdaoUniversityQingdaoShandongP.R.China Department of Oncology Shandong Cancer HospitalJinanShandongP.R.China Department of Oncology The First BethuneHospital of Jilin UniversityChangchunJilinP.R.China Department of Respiration Northern Jiangsu People’s Hospital Affiliated to Yangzhou UniversityYangzhouJiangsuP.R.China Department of Internal

Background:The initial randomized,double-blinded,actively controlled,phase III ANEAS study(NCT03849768)demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first-line therapy in epidermal growth factor receptor(EGFR)-mutated advanced non-small cell lung cancer(NSCLC).Metastatic disease in the central nervous system(CNS)remains a challenge in the management of *** study aimed to compare the efficacy of aumolertinib versus gefitinib among patients with baseline CNS metastases in the ANEAS ***:Eligible patients were enrolled and randomly assigned in a 1:1 ratio to orally receive either aumolertinib or gefitinib in a double-blinded *** with asymptomatic,stable CNS metastases were ***-up imaging of the same modality as the initial CNS imaging was performed every 6 weeks for 15 months,then every *** responsewas assessed by a neuroradiological blinded,independent central review(neuroradiological-BICR).The primary endpoint for this subgroup analysis was CNS progression-free survival(PFS).Results:Of the 429 patients enrolled and randomized in the ANEAS study,106 patients were found to have CNS metastases(CNS Full Analysis Set,cFAS)at baseline by neuroradiological-BICR,and 60 of them had CNS target lesions(CNS Evaluable for Response,cEFR).Treatment with aumolertinib significantly prolonged median CNS PFS compared with gefitinib in both cFAS(29.0 vs.8.3 months;hazard ratio[HR]=0.31;95%confidence interval[CI],0.17-0.56;P<0.001)and cEFR(29.0 vs.8.3 months;HR=0.26;95%CI,0.11-0.57;P<0.001).The confirmed CNS overall response rate in cEFRwas 85.7%and 75.0%in patients treated with aumolertinib and gefitinib,*** risk analysis showed that the estimated probability of CNS progression without prior non-CNS progression or death was consistently lower with aumolertinib than with gefitinib in patients with and without CNSmetastases at *** new safety findings were ***:The

关键词： aumolertinib brain metastasis non-small cell lung cancer third-generation EGFR-TKI